Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer

Critical Reviews in Oncology/Hematology, 04/13/2012

The two randomized trials (BOLERO–2 and TAMRAD) evaluating everolimus±endocrine therapy in a selected subgroup of HR–positive metastatic breast cancer patients have demonstrated a significant improvement in progression free survival for the combination compared to the endocrine therapy alone. The data reported so far show that the combination of target agents with endocrine therapy is effective in overcoming acquired resistance in patients with hormone receptor positive metastatic breast cancer.

Print Article Summary Cat 2 CME Report